Results 91 to 100 of about 181,578 (308)

Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies

Advanced Healthcare Materials, EarlyView.
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best, Gizem Karabiyik, Gerd Geerling, Sarah Barbara Zwingelberg, Gregor Lang, Martin Humenik   +5 more
wiley   +1 more source

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells

CPT: Pharmacometrics & Systems Pharmacology, 2019
Tisagenlecleucel is a chimeric antigen receptor–T cell therapy that facilitates the killing of CD19+ B cells. A model was developed for the kinetics of tisagenlecleucel and the impact of therapies for treating cytokine release syndrome (tocilizumab and ...
Andrew M. Stein, Stephan A. Grupp, John E. Levine, Theodore W. Laetsch, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, Bruce L. Levine, Lori Tomassian, Sweta Shah, Mimi Leung, Pai‐Hsi Huang, Rakesh Awasthi, Karen Thudium Mueller, Patricia A. Wood, Carl H. June   +15 more
doaj   +1 more source

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Novel Cell type-specific aptamer-siRNA delivery system for HIV-1 therapy [PDF]

, 2007
The successful use of small interfering RNAs (siRNAs) for therapeutic purposes requires safe and efficient delivery to specific cells and tissues. Here we demonstrate cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer. The
Haitang Li, Jiehua Zhou, John Rossi, John Zaia, Shirley Li   +4 more
core   +2 more sources

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Different domains cooperate to target the human ribosomal L7a protein to the nucleus and to the nucleoli. [PDF]

, 1997
The human ribosomal protein L7a is a component of the major ribosomal subunit. We transiently expressed in HeLa cells L7a-β-galactosidase fusion proteins and studied their subcellular localization by indirect immunofluorescence staining with anti-β ...
Giulia RUSSO, PIETROPAOLO C., RICCIARDELLI G.   +2 more
core   +1 more source

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury

Advanced Healthcare Materials, EarlyView.
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang, Wing Yan Chung, Serena M. Pulente, Yubin Lei, Khang Nguyen, Eddie Tam, Nadya M. Morrow, Ilka Lorenzen‐Schmidt, Fengxia Xiao, Augusto Zani, Dylan Burger, Hye Kyoung Sung, Erin E. Mulvihill, Gary Sweeney   +13 more
wiley   +1 more source

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer [PDF]

, 2012
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
A Lundqvist, A Somers, C Berger, CA Tran, Carolina Berger, Cornelis JM Melief, Daniel J Powell, David F Stroncek, DG Song, DJ Powell Jr, DL Porter, Francesco M Marincola, G Mostoslavsky, GG Kenter, Gustavo Mostoslavsky, J Jin, J Staerk, James R Heath, Jeffrey S Miller, JN Kochenderfer, JN Kochenderfer, John O'Shea, JS Miller, K Takahashi, L Gattinoni, L Gattinoni, L Gattinoni, L Gattinoni, LA Johnson, Luca Gattinoni, M Kalos, M Kalos, M Kalos, Mahendra Rao, Mark E Dudley, Martin A Cheever, ME Dudley, ME Dudley, Michael Kalos, Nicholas P Restifo, P Muranski, Peter Flynn, PF Robbins, RA Morgan, Richard W Childs, SA Rosenberg, Steven A Rosenberg, TS Park, X Wang   +48 more
core   +4 more sources

Microfluidic Hydroporation Platform for Effective Allogeneic CAR‐T Cell Production and Subsequent Functional Cytotoxicity Analysis

Advanced Materials Technologies, EarlyView.
The hydroporator platform employs controlled hydrodynamic deformation for efficient mRNA and CRISPR/Cas9 delivery into primary human T cells, enabling allogeneic CAR‐T cell manufacturing. It preserves cell functionality and drives potent gene editing, CAR expression, and tumor cytotoxicity, while feature‐based analysis links these functional outcomes ...
Soohyun Jeon, Sein Kim, Hyun‐Young Kim, Duck Cho, Sungsu Park, Seohyun Kim, Aram J. Chung   +6 more
wiley   +1 more source

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source